3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
3
Radiation Injuries
2
Cognitive Dysfunction
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Docetaxel
5
pembrolizumab
4
Radiotherapy
3
ulixertinib
2
Trastuzumab
2
Paclitaxel
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Erlotinib Hydrochloride
2
Carboplatin
2
Capecitabine
2
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
regorafenib
1
pertuzumab
1
palbociclib
1
osimertinib
1
oncogene protein E7, Human papillomavirus type 16
1
omipalisib
1
oblimersen
1
motexafin gadolinium
1
larotrectinib
1
ipatasertib
1
fludarabine
1
erdafitinib
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Patient Reported Outcome Measures
×
CNS
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled